TNFRSF9 and ovarian serous adenocarcinoma: Another publication reported the application of DC-pulsed mRNA encoding WT1 in ovarian carcinoma and carcinosarcoma.170 Two patients, one with serous ovarian cancer and the other with ovarian carcinosarcoma, received four weekly vaccinations, which induced increased CD137+ antigen-specific T cells, IL-2, and IFN-γ in ovarian carcinoma and CD137+ antigen-specific T cells, IL-2, and TNF-α in ovarian carcinosarcoma.